Cindy Chmielewski on ASH background

Immunotherapy – Front and Center

Cynthia Chmielewski |

Immunotherapy was front and center at this year’s American Society of Hematology’s (ASH) meeting. There even was an Education Session presented by Drs. Shah, Cohen and Borello on this topic. When I first attended the ASH Annual Meeting in 2012, immunotherapy was still in its infancy. The treatments that were being examined in clinical trials back […]

How Things Have Changed

Linda Huguelet |

I was diagnosed in 2010, and this is my seventh year to attend the American Society of Hematology (ASH) conference. As we are winding up the a last day of the conference, I can’t believe how much progress has been made. I know it’s never fast enough from a patient’s perspective, but nonetheless, the progress […]

John Deflice, myeloma patient, with backdrop of ASH conference in Orlando 2019

“Baby, baby, baby what will it be?” —Prince

John DeFlice |

With so many great studies covered at ASH 2019, what will take home the honors for the best outstanding oral presentation? Will it be a Chimeric Antigen Receptor (CAR) or Bispecific T-cell Engager (BiTEs) trials, or will it be a new four-drug combination trial? How about one study that has a 100% response rate in myeloma […]

Day 3 – “Myeloma Monday” Saving the Best for Last

Jack Aiello |

Before providing details of our final full day at ASH (noting #abstract where applicable), let me review some activities from yesterday (Sunday 12/8/19). In the morning I attended a number of myeloma cancer care delivery abstracts (#383, #423, #424) where topics like diversity and racial/socioeconomic impact were discussed. Black/African-American patients are less likely to have […]

Immunotherapy at #ASH19

Jim Omel |

Immunotherapy has definitely been the center of myeloma attention at ASH. Sessions on Bi-specific T-cell Engagers and CAR-T were many and were well attended. Several Chinese oral abstract presentations Monday morning were inspiring and promising. Deepu Madduri, MD, showed a waterfall plot with 100% response rate in a phase I/phase II study of JNJ4528 BCMA-Targeted CAR-T cell […]

Four years ago….

Yelak Biru |

“During a two-week span in November, the Food and Drug Administration approved three new drugs to treat multiple myeloma, a rare form of blood cancer that kills an estimated 11,000 Americans a year. The approvals, along with others in recent years, are beginning to alter the prognosis of a disease that once amounted to a death […]

Teresa Miceli on American Society of Hematology background

‘Tis The Season – Heme, Heme, Heme

Teresa Miceli |

The American Society of Hematology (ASH) Annual Meeting will take place Dec. 7 through Dec. 10 in Orlando, Florida. For many, this time of year is the high point of the holiday season. We give thanks for our blessings, share gifts with our friends and family, and celebrate all of the promise that a New […]